PCN41 Cost-Effectiveness of Pembrolizumab in Combination with Chemotherapy in the 1ST LINE Treatment of Metastatic NSCLC in Taiwan

Abstract

Authors

Y.J. Shao A. Arunachalam R. Insinga S. Lei S.C. Tan C. Spiteri

Full Text Cite This Article
Back to Volume 22, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×